In addition, recent studies indicate that the IDH1 wildtype enzyme may be overexpressed in over 60% of glioblastomas [114,115], suggesting that PET tracers with limited selectivity for mutated isoforms could give false positive results when used to assess the IDH status in these patients. Here, IDH2 is linked to glioblastoma.